EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSMMUG00000021577
Gene Symbol: DHCR24
5 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSMMUG00000006139
Gene Symbol: HMGCR
5 Cross references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSMMUG00000011459
Gene Symbol: PDPK1
5 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSMMUG00000016454
Gene Symbol: HPD
5 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S11-Like

Ensembl ID : ENSMMUG00000044284
Gene Symbol: LOC706532
4 Cross references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S12

Ensembl ID : ENSMMUG00000006463
Gene Symbol: LOC706087
4 Cross references
147 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S26-Like

Ensembl ID : ENSMMUG00000058071
Gene Symbol: LOC106999718
4 Cross references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S3a

Ensembl ID : ENSMMUG00000002676
Gene Symbol: LOC703455
4 Cross references
172 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S4, X Isoform-Like

Ensembl ID : ENSMMUG00000029338
Gene Symbol: LOC702514
4 Cross references
144 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein Sa-Like

Ensembl ID : ENSMMUG00000022965
Gene Symbol: LOC106996346
4 Cross references
156 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein Sa-Like

Ensembl ID : ENSMMUG00000004941
Gene Symbol: LOC710477
4 Cross references
172 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5'-Nucleotidase Ecto

Ensembl ID : ENSMMUG00000005442
Gene Symbol: NT5E
5 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).